SYGNIS

Madrid, Spain Founded: 1997 • Age: 29 yrs
SYGNIS provides molecular biology reagents for research and laboratory applications.
Request Access

About SYGNIS

SYGNIS is a company based in Madrid (Spain) founded in 1997. It operates as a B2B. SYGNIS has completed 4 acquisitions, including CBS Scientific, Expedeon and Innova Biosciences. SYGNIS operates in a competitive market with competitors including Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.

  • Headquarter Madrid, Spain
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Jurisdiction Bangalore North, Karnataka, India
Operational Areas
Healthcare → Medical Devices & Diagnostics
Key Metrics
  • Annual Revenue
    $403.09 K (USD)
    19.31
    as on Mar 31, 2022
  • Net Profit
    $26.11 K (USD)
    -14.87
    as on Mar 31, 2022
  • EBITDA
    $31.2 K (USD)
    28.43
    as on Mar 31, 2022
  • Latest Funding Round
    $2.38 M (USD), Debt – Conventional

    May 09, 2018

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of SYGNIS

  • Total Funding
  • Total Rounds 11
  • Last Round Debt – Conventional — $2.4M
  • First Round

    (06 Nov 2008)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2018 Amount Post-IPO - SYGNIS Valuation

investors

May, 2018 Amount Debt – Conventional - SYGNIS Valuation

investors

Mar, 2018 Amount Post-IPO - SYGNIS Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by SYGNIS

SYGNIS has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include CBS Scientific, Expedeon and Innova Biosciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Reagents and kits for protein-based research are developed and supplied.
2003
Antibody labeling and bioconjugation kits are developed and marketed.
2002
Specializes in immunoassay technology
2001
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - SYGNIS

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sygnis Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SYGNIS

SYGNIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biological reagents and antibodies are developed for life science research.
domain founded_year HQ Location
Developer of cell culture media and ancillary reagents for life science research
domain founded_year HQ Location
Proteins, antibodies, and molecular tools are manufactured for research applications.
domain founded_year HQ Location
Research services, reagents, and kits for biotech applications are provided.
domain founded_year HQ Location
Molecular diagnostic device and kits
domain founded_year HQ Location
Molecular biology reagents and kits are supplied for research applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sygnis

Frequently Asked Questions about SYGNIS

When was SYGNIS founded?

SYGNIS was founded in 1997 and raised its 1st funding round 11 years after it was founded.

Where is SYGNIS located?

SYGNIS is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.

What is the annual revenue of SYGNIS?

Annual revenue of SYGNIS is $403.09K as on Mar 31, 2022.

What does SYGNIS do?

SYGNIS, based in Madrid, focuses on providing healthcare solutions, advancing biotech innovations, life sciences, and reagents and supplies. SYGNIS provides molecular biology reagents for research and laboratory applications. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.

Who are the top competitors of SYGNIS?

SYGNIS's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.

How many acquisitions has SYGNIS made?

SYGNIS has made 4 acquisitions, including CBS Scientific, Expedeon, and Innova Biosciences.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available